Table 13.5Summary of studies comparing paricalcitol with placebo

StudyPopulationDuration (months)Paricalcitol (N)Placebo (N)OutcomeSize effect
3423 pooled RCTs: CKD, iPTH ≥150 pg/ml, Ca 1.99–2.40 mmol/l and PO4 ≤1.68 mmol/l.6101108Change iPTH (%)Paricalcitol: −45.2% (max)
Placebo: +13.9% (max)
p<0.001 between groups
1011082 consecutive decreases ≥30% of iPTHParicalcitol: 91%
Placebo: 13%
p<0.001 between groups
100104Change osteocalcin, ng/mlParicalcitol: −21.6 ng/ml
Placebo: +10.7 ng/ml
p<0.001 between groups
101107Change Bone-specific alkaline phosphatase (μg/l)Paricalcitol: −7.89 μg/l
Placebo: −1.44 μg/l, p<0.001 between groups
8293Change in GFR:Paricalcitol: −2.52 ml/min/1.73 m2, (–10.4%)
Placebo: −1.57 ml/min/1.73 m2 (–6.95%)
NS between treatments.

From: 13, Specific complications of CKD – renal bone disease

Cover of Chronic Kidney Disease
Chronic Kidney Disease: National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care.
NICE Clinical Guidelines, No. 73.
National Collaborating Centre for Chronic Conditions (UK).
Copyright © 2008, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.